SUBSCRIBE
SUBSCRIBE
News   Business

Cabernet Pharmaceuticals and Eli Lilly and Company Form Pharmacogenetics Alliance to Help Deliver Tailored Therapeutics to Patients

November 6, 2008 | 
1 min read
DURHAM, N.C. & INDIANAPOLIS--(BUSINESS WIRE)--Cabernet Pharmaceuticals, Inc. and Eli Lilly and Company (NYSE:LLY) today announced an alliance to further integrate pharmacogenetics into Lilly’s drug-development efforts.
Alliances
Eli Lilly and Company
MORE ON THIS TOPIC
Dashed line from pills isolated on white
Cancer
Ipsen Pulls Cancer Drug Amid Risk of Secondary Malignancies
March 9, 2026
 · 
2 min read
 · 
Tristan Manalac
Illustration of cardboard box filled with office supplies, a computer keyboard, lamp, and a potted plant
Layoff Tracker
Vertex Terminates 20 in Reorganization Push
March 9, 2026
 · 
32 min read
 · 
BioSpace Editorial Staff
Brain tumor medical poster. Cancer, metastasis or benign in the human head or in the nerves, pituitary gland, pineal gland, and membranes that cover the surface of the brain 3D vector illustration
Mergers & acquisitions
Servier Adds to Childhood Brain Tumor Portfolio With $2.5B Day One Buy
March 6, 2026
 · 
1 min read
 · 
Annalee Armstrong
Creative collage illustration of financial business. Two businessmen shaking hands for partners agreement. Conceptual illustration of success deal, corporate ethic, connection.
Cardiovascular disease
Alnylam Unites With Tenaya in Potential $1B+ Pact To Find New Genetic Heart Disease Targets
March 5, 2026
 · 
2 min read
 · 
Heather McKenzie